GlassScriptPhysician profile
Charlene Sweeney
NPI 1700866415
$567.58
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $101 · 2022: $30.43.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $223.53 | 2019-2020 | |
| Genzyme Corporation | $78.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $55.66 | 2019-2020 | |
| Acorda Therapeutics, INC | $36.87 | 2019 | |
| Emd Serono, INC. | $31.72 | 2019 | |
| Boston Scientific Corporation | $30.43 | 2022 | |
| Ucb, INC. | $29.35 | 2019 | |
| Genentech USA, INC. | $28.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.53 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlene Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.